Paroxetine in the treatment of generalised anxiety disorder

Bibliography

• WITTCHEN H-U, ZHAO S, KESSLER RC, EATON WW: DSM-III-R generalized anxiety disorder in the national comorbidity survey. Arch. Gen. Psychiatry (1994) 51:355–364.
   PubMedGoogle Scholar
• KATON W, VON KORFF M, LINE E et al.: Distressed high utilizers of medical care DSM-III-R diagnoses and treatment needs. Gen Hosp. Psychiatry (1990) 12:355–362.
   PubMed Web of Science ®Google Scholar
• BALLENGER JC, DAVIDSON JRT LECRUBIER Y et al.: Consensus Statement on Generalized Anxiety Disorder from the International Consensus Group on Depression and Anxiety. I Clin. Psychiatry (2001) 62\(Suppl. 11):53–58.
   Google Scholar
• •Discusses treatment strategies for GAD, first-line and otherwise, as well as giving a general overview of the risks and benefits of the different classes of medications used to treat GAD.
   Google Scholar
• WITTCHEN H-U, BOYER P: Screening for anxiety disorders: sensitivity and specifity of the anxiety screening questionnaire (ASQ-15). Br. I Psychiatry Sapp]. (1998) 34:10–17.
   Google Scholar
• AKISKAL HS: Toward a definition of generalized anxiety disorder as an anxious temperament type. Acta Psychiatr. Scand. (1998) 98\(Suppl. 393):66–73.
   Google Scholar
• RICKELS K, SCHWEIZER E: Long term treatment of anxiety disorders: Maintenance treatment studies in anxiety disorders: Some methodological notes. Psychopharmacol Bull. (1995) 31:115–123.
   PubMedGoogle Scholar
• STEIN DJ: Comorbidity in generalized anxiety disorder: impact and implications. Clin. Psychiatry (2001) 62\(Suppl. 11):29–34.
   Google Scholar
• FRANCES A, FIRST MB, PINCUS HA, WIDIGER TA: Diagnostic and Statistical Manual of Mental Disorders (4th edit) Text Revision. American Psychiatric Association (2000):429–484.
   Google Scholar
• RYNN MA, SIQUELAND L, RICKELS K: Sertraline in children with generalized anxiety disorder: a controlled study. Am. j Psychiatry (2001) 158:2008–2014.
   PubMed Web of Science ®Google Scholar
• WITTCHEN H-U, LINDEN M, SCHWARZER W, REIMANN D, BOERNER RJ, BANDELOW: GAD-P Studie. Bundesweite Studie `Generalisierte Angst und Depression im primaeraerztlichen Bereich'. Fortschr. Med. (2001) 119(Sonderheft 1):1–49.
   Google Scholar
• MAISSON AO, WARSHAW MG, KELLER MB: Quality of life and psychiatric comorbidity in panic disorder and generalized anxiety disorder. Am. J. Psychiatry (1993) 150:600–607.
   PubMed Web of Science ®Google Scholar
• RAJ A, SHEEHAN DV: Antidepressants in the Treatment of Generalized Anxiety Disorder. In: Generalized Anxiety Disorder: Symptomatology, Pathogenesis and Management. Nutt D, Rickels K, Stein DJ (Eds), Martin Dunitz Ltd., London, UK (2002):137–152.
   Google Scholar
• NUTT DJ, BAILEY DJ: The Neurobiology of Generalized Anxiety Disorder. In: Generalized Anxiety Disorder: Symptomatology, Pathogenesis and Management. Nutt D, Rickels K, Stein DJ (Eds), Martin Dunitz Ltd., London, UK (2002)59–70.
   Google Scholar
• STAHL S: Essential Psychopharmacology: Neuroscientific Bash and Practical Applications (2'd edit). Cambridge University Press, Cambridge, UK (2000):199–364.
   Google Scholar
• STAHL SM: Don't Ask, Don't Tell, but Benzodiazepines Are Still the Leading Treatments for Anxiety Disorder. J. Clin. Psychiatry (200 2) 63(9):756–757.
   Google Scholar
• HOEHN-SARIC R, MCLEOD DR, ZIMMERLI WD: Differential effects of alprazolam and imipramine in generalized anxiety disorder: somatic versus psychic symptoms.' Clin. Psychiatry (1988) 49:293–301.
   PubMed Web of Science ®Google Scholar
• •Describes the concepts of somatic versus psychic anxiety, and how the benzodiazepines are more effective in treating somatic symptoms, whereas the antidepressants are more efficacious in treating psychic symptoms.
   Google Scholar
• RICKELS K, DOWNING RW, SCHWEIZER E, HASSMAN H: Antidepressants for the treatment of generalized anxiety disorder- a placebo-controlled comparison of imipramine, trazodone and diazepam. Arch. Gen. Psychiatry (1993) 50:884–895.
   PubMed Web of Science ®Google Scholar
• •Describes the concepts of somatic versus psychic anxiety, and how the benzodiazepines are more effective in treating somatic symptoms, whereas the antidepressants are more efficacious in treating psychic symptoms.
   Google Scholar
• NINAN PT, COLE JO, YONKERS KA: Nonbenzodiazepine amdolytics. In: Textbook of Psychopharmacology (2'd edit). Schatzberg AF, Nemeroff CB (Eds), American Psychiatric Press, Washington DC, USA (2001):286–300.
   Google Scholar
• ENKELMANN R Alprazolam versus buspirone in the treatment of outpatients with generalized anxiety disorder. Psychopharmacology (1991) 105:428–432.
   PubMed Web of Science ®Google Scholar
• FEIGHNER JP, MERIDETH CH, HENDRICKSON GA: A double-blind comparison of buspirone and diazepam in outpatients with generalized anxiety disorder. j. Clin. Psychiatry (1982) 43:103–108.
   PubMed Web of Science ®Google Scholar
• RICKELS K, WEISMAN K, NORSTAD N et al.: Buspirone and diazepam in anxiety: a controlled study. .1. Clin. Psychiatry (1982) 43:81–86.
   Google Scholar
• LAAKMAN G, SCHULE C, LORKOWSKI G et al.: Buspirone and lorazepam in the treatment of generalized anxiety disorder in outpatients. Psychopharmacology (1998) 136:357–366.
   PubMed Web of Science ®Google Scholar
• STRAND M, HETTA J, ROSEN A et al.:A double-blind, controlled trial in primary care patients with generalized anxiety: a comparison between buspirone and oxazepam.j Gin. Psychiatry (1990) 51(Suppl.):40–45.
   Google Scholar
• RICKELS K SCHWEIZER E, CSANALOSI I, CASE WG, CHUNG H: Long-term treatment of anxiety and risk of withdrawal. Arch. Gen. Psychiatry (1988) 45(5):444–450.
   PubMedGoogle Scholar
• KAHN RJ, MCNAIR DM, LIPMAN RS et al.: Imipramine and chlordiazepoxide in depressive and anxiety disorders. II. Efficacy in anxious outpatients. Arch. Gen. Psychiatry (1986) 43:79.
   PubMed Web of Science ®Google Scholar
• DAVIDSON JRT, DUPONT RL, HEDGES D, HASKINS JT et al.,: Efficacy, safety and tolerability of venlafaxine XR extended release and buspirone in outpatients with generalized anxiety disorder.' Gin. Psychiatry (1999) 60:528–535.
   Google Scholar
• RICKELS K, POLLACK MH, SHEEHAN DV et al.: Efficacy of extended release venlafaxine in non-depressed outpatients with generalized anxiety disorder. Am. .1. Psychiatry (2000) 157(6):968–974.
   Google Scholar
• GELENBERG AJ, LYDIARD RB, RUDOLPH RL, AGUIAR L, HASKINS JT, SALINAS E: Efficacy of venlafaxine extended-release capsules in nondepressed outpatients with generalized anxiety disorder: a 6-month randomized controlled trial. "AMA (2000) 283:3082–3088.
   PubMed Web of Science ®Google Scholar
• ALL GULANDER C, HACKETT D, SALINAS E: Venlafaxine extended release (ER) capsules in the treatment of generalized anxiety disorder: twenty-four-week placebo-controlled dose ranging study. Br. J. Psychiatry (2001) 179:15–22.
   PubMed Web of Science ®Google Scholar
• WAGSTAFF AJ, CHEER SM, MATHESON AJ, ORMROD D, GOA KL: Paroxetine: an update of its use in psychiatric disorders in adults. Drugs (2002) 62:655–703.
   PubMed Web of Science ®Google Scholar
• ••A good review with a fairly comprehensivelist of references which covers the use of paroxetine in a wide range of psychiatric disorders.
   Google Scholar
• ALLGULANDER C: Efficacy of sertraline for the acute treatment of generalized anxiety disorder (GAD). Poster presented at the Anxiety Disorders Association of America Conference. © 2003 Anxiety Disorders Association of America (2003).
   Google Scholar
• WALKUP JT, LABELLARTE MJ, RIDDLE MA et al.: Fluvoxamine for the treatment of anxiety disorders in children and adolescents. N Engl. .1. Med. (2001) 344(17):1279–1285.
   Google Scholar
• GOODMAN WK, BOSE A, WANG Q: Escitalopram 10mg/day is Effective in the treatment of generalized anxiety disorder. Poster presented at the 42'd Annual Meeting of the American College of Neuropsychopharmacology San Juan, Puerto Rico, December 7-11(2003).
   Google Scholar
• Glaxo-SmithKline Corporation: Paxil (paroxetine hydrochloride) Prescribing Information. Last revised August (2003).
   Google Scholar
• GOODMAN D: Diagnosis and treatmentof refractory depression. Sheppard Pratt Psychiatric Lecture Series (1999) 26(1).
   Google Scholar
• ROCCA P, FONZO V, SCOTTA M, ZANALDA E, RAVIZZA L: Paroxetine efficacy in the treatment of generalized anxiety disorder. Acta Psychiatc Scand. (1997) 95:444–450.
   PubMed Web of Science ®Google Scholar
• POLLACK MH, ZANINELLI R, GODDARD A et al.: Paroxetine in the treatment of generalized anxiety disorder: results of a placebo controlled, flexible dosage trial. J. Gin. Psychiatry (2001) 62:350–357.
   Google Scholar
• •Describes pivotal trials of paroxetine in treating GAD.
   Google Scholar
• RICKELS K, ZANINELLI R, MCCAFFERTY J, BELLEW K, IYENGAR M, SHEEHAN DV: Paroxetine treatment of generalized anxiety disorder: a double-blind, placebo-controlled study. Am. J. Psychiatry (2003) 160:749–756.
   PubMed Web of Science ®Google Scholar
• •Describes pivotal trials of paroxetine in treating GAD.
   Google Scholar
• STOCCHI F, NORDERA G, JOKINEN J et al.: Efficacy and tolerability of paroxetine for the long-term treatment of generalized anxiety disorder. J. Gin. Psychiatry (2003) 64:250–258.
   Google Scholar
• SUSSMAN N, GINSBERG D: Weight gain associated with SSRIs. Primary Psychiatry (1998) 5:28–37.
   Google Scholar
• NEWPORT DJ, STOWE ZN: Clinical management of perinatal depression: focus on paroxetine. Psychopharmacol Bull. (2003) 37\(Suppl. 1):148–166.
   Google Scholar
• GOLDEN RN: Efficacy and tolerability ofcontrolled-release paroxetine. Psychopharmacol Bull. (2003) 37\(Suppl. 1):176–186.
   Google Scholar